Title: PREVENT HPV Cancers Act of 2021
Policy area: Health

Summary:
Promoting Resources to Expand Vaccination, Education and New Treatments for HPV Cancers Act of 2021 or the PREVENT HPV Cancers Act of 2021
This bill supports efforts to increase human papillomavirus (HPV) vaccination rates and otherwise prevent and treat cervical cancer and other cancers associated with that virus.
Specifically, the Centers for Disease Control and Prevention (CDC) must educate the public about HPV vaccinations. The CDC must consult with the National Academy of Medicine, health departments, and other stakeholders on this effort. In addition, recipients of project grants to establish and maintain preventive health services may use grant funds for state immunization information systems.
Furthermore, the bill directs the National Cancer Institute to expand research activities focused on HPV-associated cancers and reauthorizes the National Breast and Cervical Cancer Early Detection Program. This program provides access to screening and diagnostic services to uninsured and other underserved individuals.

[Congressional Bills 117th Congress]
[From the U.S. Government Publishing Office]
[H.R. 1550 Introduced in House (IH)]

<DOC>






117th CONGRESS
  1st Session
                                H. R. 1550

    To amend the Public Health Service Act to provide for a public 
awareness campaign with respect to human papillomavirus, and for other 
                               purposes.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                             March 3, 2021

  Ms. Castor of Florida (for herself and Ms. Schrier) introduced the 
   following bill; which was referred to the Committee on Energy and 
                                Commerce

_______________________________________________________________________

                                 A BILL


 
    To amend the Public Health Service Act to provide for a public 
awareness campaign with respect to human papillomavirus, and for other 
                               purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Promoting Resources to Expand 
Vaccination, Education and New Treatments for HPV Cancers Act of 2021'' 
or the ``PREVENT HPV Cancers Act of 2021''.

SEC. 2. FINDINGS.

    Congress finds the following:
            (1) The human papillomavirus (referred to in this Act as 
        ``HPV'') causes six different types of cancer (anal, cervical, 
        oropharynx, penile, vaginal, and vulvar).
            (2) Almost 35,000 cases of cancer are caused by HPV each 
        year impacting both women and men.
            (3) About 90 percent of cervical and anal cancers are 
        thought to be caused by HPV.
            (4) Black and Hispanic women are more likely to get HPV-
        associated cervical cancer than women of other races and 
        ethnicities.
            (5) Approximately 60 to 70 percent of oropharynx cancer is 
        tied to HPV.
            (6) Most HPV infections that can lead to cancer can be 
        prevented by vaccines.
            (7) HPV vaccines can also help prevent recurrent 
        respiratory papillomatosis, anal and genital warts.
            (8) Vaccination for HPV is approved for men and women.
            (9) The vaccines are most effective if administered when an 
        individual is between the ages of 9 and 12.
            (10) Only about half of adolescents have completed the HPV 
        vaccine series.
            (11) Certain populations, like adolescents in rural areas 
        and males are less likely to receive the HPV vaccine.
            (12) Health providers' recommendation of the vaccine is 
        critical to getting adolescents vaccinated

SEC. 3. HPV VACCINE PUBLIC AWARENESS CAMPAIGN.

    Section 317 of the Public Health Service Act (42 U.S.C. 247b) is 
amended by adding at the end the following new subsection:
    ``(o) HPV Vaccine Public Awareness Campaign.--
            ``(1) In general.--The Secretary, acting through the 
        Director of the Centers for Disease Control and Prevention, 
        shall carry out a national campaign to--
                    ``(A) increase awareness of the importance of HPV 
                vaccination;
                    ``(B) combat misinformation about HPV vaccination; 
                and
                    ``(C) increase HPV vaccination rates and completion 
                of the vaccine series, especially among males.
            ``(2) Consultation.--In carrying out the national campaign 
        required by paragraph (1), the Secretary shall consult with the 
        National Academy of Medicine, including health care providers 
        and public health associations, nonprofit organizations 
        (including those that represent communities most impacted by 
        HPV-associated cancers and communities with low vaccination 
        rates), State and local public health departments, elementary 
        and secondary education organizations (including student and 
        parent organizations), and institutions of higher education, to 
        solicit advice on evidence-based information for policy 
        development and program development, implementation, and 
        evaluation.
            ``(3) Requirements.--The national campaign required by 
        paragraph (1) shall--
                    ``(A) include the use of evidence-based media and 
                public engagement;
                    ``(B) be carried out through competitive grants or 
                cooperative agreements awarded to one or more private, 
                nonprofit entities with a history developing and 
                implementing similar campaigns;
                    ``(C) include the development of culturally and 
                linguistically competent resources that shall be 
                tailored for--
                            ``(i) communities with high rates of--
                                    ``(I) unvaccinated individuals, 
                                including males;
                                    ``(II) individuals with unique 
                                health care needs (such as lesbian, 
                                gay, bisexual, transgender, and queer 
                                individuals);
                                    ``(III) individuals with high rates 
                                of cervical cancer and other HPV-
                                associated cancers (such as Black and 
                                Hispanic women); and
                                    ``(IV) populations impacted by the 
                                increase in oropharynx cancers;
                            ``(ii) rural communities; and
                            ``(iii) such other communities as the 
                        Secretary determines appropriate;
                    ``(D) include the dissemination of HPV vaccination 
                information and communication resources to health care 
                providers and health care facilities (including primary 
                care providers, community health centers, dentists, 
                obstetricians, and gynecologists), and such providers 
                and such facilities for pediatric care, State and local 
                public health departments, elementary and secondary 
                schools, and colleges and universities;
                    ``(E) be complementary to, and coordinated with, 
                any other Federal efforts with respect to HPV 
                vaccination;
                    ``(F) include message testing to identify 
                culturally competent and effective messages for 
                behavioral change; and
                    ``(G) include the award of grants or cooperative 
                agreements to State, local, and Tribal public health 
                departments--
                            ``(i) to engage with communities specified 
                        in subparagraph (C), local education agencies, 
                        health care providers, community organizations, 
                        or other groups the Secretary determines are 
                        appropriate to develop and deliver effective 
                        strategies to increase HPV vaccination rates; 
                        and
                            ``(ii) to disseminate culturally and 
                        linguistically competent resources on the 
                        National Breast and Cervical Cancer Early 
                        Detection Program and where an individual can 
                        access the screenings locally.
            ``(4) Options for dissemination of information.--The 
        national campaign required by paragraph (1) may--
                    ``(A) include the use of--
                            ``(i) social media, television, radio, 
                        print, the internet, and other media;
                            ``(ii) in-person or virtual public 
                        communications; and
                            ``(iii) recognized, trusted figures;
                    ``(B) be targeted to specific groups and 
                communities specified in paragraph (3)(C); and
                    ``(C) include the dissemination of information 
                highlighting each of the following:
                            ``(i) Recommended age range to get the HPV 
                        vaccine.
                            ``(ii) The benefits of getting vaccinated 
                        against HPV, including the potential to not 
                        acquire HPV-associated cancers.
                            ``(iii) HPV vaccine safety and the systems 
                        in place to monitor such safety.
            ``(5) Authorization of appropriations.--There is authorized 
        to be appropriated to carry out this subsection $5,000,000 for 
        each of fiscal years 2021 through 2025.''.

SEC. 4. STATE IMMUNIZATION INFORMATION SYSTEM ENHANCEMENT.

    Section 317(k) of the Public Health Service Act (42 U.S.C. 247b(k)) 
is amended--
            (1) in paragraph (1)--
                    (A) in subparagraph (C), by striking ``and'' at the 
                end;
                    (B) in subparagraph (D), by striking the period at 
                the end and inserting ``; and''; and
                    (C) by adding at the end the following:
                    ``(E) State immunization information systems.'';
            (2) in paragraph (2)--
                    (A) in subparagraph (C), by striking ``and'' at the 
                end;
                    (B) in subparagraph (D), by striking the period at 
                the end and inserting ``; and''; and
                    (C) by adding at the end the following:
                    ``(E) State immunization information systems.''; 
                and
            (3) by adding at the end the following:
            ``(5) In addition to any funds made available under 
        subsection (j) to carry out this subsection, there are 
        authorized to be appropriated to carry out this subsection 
        $50,000,000 for each of fiscal years 2021 through 2025.''.

SEC. 5. EXPANDING RESEARCH AND EDUCATION WITH RESPECT TO HPV-ASSOCIATED 
              CANCERS.

    Part B of title IV of the Public Health Service Act (42 U.S.C. 284 
et seq.) is amended by adding at the end the following new section:

``SEC. 409K. HPV-ASSOCIATED CANCERS.

    ``(a) In General.--The Secretary, acting through the Director of 
the National Cancer Institute, shall expand, intensify, and coordinate 
programs to conduct and support research with respect to HPV-associated 
cancers.
    ``(b) Coordination With Other Institutes.--The Secretary, acting 
through the Director of the National Cancer Institute, shall coordinate 
activities carried out by the Director pursuant to subsection (a) with 
similar activities carried out by other national research institutes 
and agencies of the National Institutes of Health to the extent that 
those Institutes and agencies have responsibilities that are related to 
HPV-associated cancers.
    ``(c) Authorization of Appropriations.--For purposes of carrying 
out this section, there is authorized to be appropriated $10,000,000 
for each of fiscal years 2021 through 2025.
    ``(d) HPV-Associated Cancer.--In this section, the term `HPV-
associated cancer' means cancer associated with the human 
papillomavirus.''.

SEC. 6. BREAST AND CERVICAL CANCER EARLY DETECTION PROGRAM.

    (a) In General.--Section 1510(a) of the Public Health Service Act 
(42 U.S.C. 300n-5(a)) is amended by striking ``and $275,000,000 for 
fiscal year 2012'' and inserting ``$275,000,000 for fiscal year 2012, 
and $300,000,000 for each fiscal years 2021 through 2025''.
    (b) Coordinating Committee.--Section 1501(d) of the Public Health 
Service Act (42 U.S.C. 300k(d)) is amended--
            (1) in the subsection heading, by striking ``2020'' and 
        inserting ``2030''; and
            (2) by striking ``2020'' and inserting ``2025''.

SEC. 7. REPORT TO CONGRESS.

    Not later than 2025, the Secretary of Health and Human Services 
shall submit to the Committee on Energy and Commerce of the House of 
Representatives and the Committee on Health, Education, Labor and 
Pensions of the Senate a report--
            (1) that contains a qualitative assessment of the campaign 
        under subsection (o) of section 317 of the Public Health 
        Service Act (42 U.S.C. 247b) and the activities conducted under 
        such campaign; and
            (2) on, with respect to the impact on cancer associated 
        with human papillomavirus--
                    (A) the activities conducted under subsection (o) 
                of section 317 of the Public Health Service Act (42 
                U.S.C. 247b), as added by section 3;
                    (B) research conducted under subsection (k) of such 
                section, pursuant to the amendments made by section 4; 
                and
                    (C) section 409K of the Public Health Service Act, 
                as added by section 5.
                                 <all>